[1] Aberg F, Helenius-Hietala J, Puukka P, et al. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology, 2018,67:2141-2149.
[2] Nguyen TA, DeShazo JP, Thacker LR, et al. The worsening profifile of alcoholic hepatitis in the United States. Alcohol Clin Exp Res,2016,40:1295-1303.
[3] Stickel F, Moreno C, Hampe J, et al. The genetics of alcohol dependence and alcohol-related liver disease. J Hepatol,2017,66:195-211.
[4] Buch S, Stickel F, Trepo E, et al. A genome-wide association study confifirms PNPLA3 and identififies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet,2015,47:1443-1448.
[5] Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol,2018,68:268-279.
[6] Abul-Husn NS, Cheng X, Li AH, et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N Engl J Med,2018,378:1096-1106.
[7] Crabb DW, Bataller R, Chalasani NP, et al. Standard defifinitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology,2016,150:785-790.
[8] Lackner C, Spindelboeck W, Haybaeck J, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol,2017,66:610-618.
[9] Altamirano J, Miquel R, Katoonizadeh A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology,2014,146(1231-1239):e1231-1236.
[10] Tiniakos DG, Anstee QM, Burt AD. Macsween’s pathology of the liver (seventh edition). Elsevier; 2018.
[11] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management Of Alcohol-Related Liver Disease. J Hepatol,2018,69:154-181.
[12] Thiele M, Detlefsen S, Sevelsted Moller L, et al. Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fifibrosis and cirrhosis.Gastroenterology,2016,150:123-133.
[13] Thiele M, Madsen BS, Hansen JF, et al. Accuracy of the enhanced liver fifibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fifibrosis in patients with alcoholic liver disease. Gastroenterology,2018,154:1369-1379.
[14] Voican CS, Louvet A, Trabut JB, et al. Transient elastography alone and in combination with FibroTest ((R)) for the diagnosis of hepatic fifibrosis in alcoholic liver disease. Liver Int, 2017,37:1697-1705.
[15] Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fifibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol,2018,15:274-282.
[16] Liangpunsakul S, Crabb DW. Early detection of alcoholic liver disease: are we a step closer? Gastroenterology,2016,150:29-31.
[17] Westwood G, Meredith P, Atkins S, et al. Universal screening for alcohol misuse in acute medical admissions is feasible and identififies patients at high risk of liver disease. J Hepatol,2017,67:559-567.
[18] Louvet A, Labreuche J, Artru F, et al.Main drivers of outcome differ between short term and long term insevere alcoholic hepatitis: a prospective study. Hepatology,2017,66:1464-1473.
[19] Gao B, Xu MJ, Bertola A, et al. Animal models of alcoholic liver disease: pathogenesis and clinical relevance. Gene Expr,2017,17:173-186.
[20] Ghosh Dastidar S, Warner JB, Warner DR, et al. Rodent models of alcoholic liver disease: role of binge ethanol administration. Biomolecules,2018,8.pii:E3. |
